An investigational new drug (IND) application for SNS-101, a conditionally active VISTA-blocking antibody, has been submitted to the US Food and Drug Administration (FDA) for a phase 1/2 clinical trial in patients with solid tumours, according to Sensei Biotherapeutics, Inc., an immuno-oncology company.
A conditionally active human monoclonal IgG1 antibody called SNS-101 is intended to specifically block the VISTA checkpoint in the tumour microenvironment, which suppresses T lymphocytes by interacting with the PSGL-1 receptor. Preclinical research has shown that SNS-101 has the potential to dramatically improve the anti-tumor effects of PD-1 blockade, limit tumour development when used alone, prevent poor pharmacokinetics from target-mediated drug disposition, and reduce the danger of cytokine release syndrome. SNS-101 will be examined by Sensei as a cutting-edge therapy for patients with solid malignancies, both alone and in combination with existing treatments.
Sensei Biotherapeutics is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Sensei creates conditionally active treatments using its TMAb (Tumour Microenvironment Activated biologics) platform that are intended to selectively disable checkpoints and other inhibitory signals in the tumour microenvironment to free T cells to attack tumours.
